Tri Locum Partners LP Acquires Shares of 89,453 Gilead Sciences, Inc. $GILD

Key Points

• Tri Locum Partners LP has acquired a new stake in Gilead Sciences, purchasing 89,453 shares valued at approximately $10 million, making it the fund's 9th largest position.
• Gilead Sciences recently reported earnings per share of $2.01, exceeding analyst estimates, and has provided FY 2025 guidance of between 7.950 to 8.250 EPS.
• The company has announced a quarterly dividend of $0.79 per share, indicating a 2.8% yield, with a payout ratio of 62.95%.

Tri Locum Partners LP acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 89,453 shares of the biopharmaceutical company's stock, valued at approximately $10,023,000. Gilead Sciences accounts for about 5.1% of Tri Locum Partners LP's holdings, making the stock its 9th largest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Nissay Asset Management Corp Japan ADV increased its position in Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its position in Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares during the last quarter. Mufg Securities Americas Inc. acquired a new position in Gilead Sciences during the fourth quarter worth approximately $1,699,000. ASR Vermogensbeheer N.V. acquired a new position in Gilead Sciences during the first quarter worth approximately $11,688,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences by 4.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after purchasing an additional 13,194 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,371,330 in the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 0.4%

Shares of Gilead Sciences stock traded up $0.41 during trading hours on Friday, hitting $112.97. The company's stock had a trading volume of 4,629,720 shares, compared to its average volume of 6,327,395. The business has a fifty day moving average of $113.01 and a 200 day moving average of $109.63. The company has a market capitalization of $140.17 billion, a PE ratio of 22.50, a P/E/G ratio of 0.70 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $77.74 and a 1-year high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 1.4% on a year-over-year basis. During the same period last year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Analyst Ratings Changes

Several brokerages recently commented on GILD. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.